Participate in the GLaD Feasibility study

Have you recently received, but not yet started, a prescription for a GLP-1 agonist medication to help you manage your weight or your diabetes?

The changes to weight and blood glucose management are well documented after starting a GLP-1 agonist medication. However, the changes to dietary intake, food preferences and eating behaviours are less characterised, but may impact other aspect of health. This project aims to explore the initial short-term effects of GLP-1 agonist medication commencement on dietary intake, food preferences and eating behaviours over a 3-month period in adults.

• This study is conducted remotely - you can live anywhere!
• 3 months duration

All participants will receive:

• Personalised results of dietary intake and behaviours
• Remuneration for completing the surveys
• Optional: body composition scans (Melbourne-based participants only)

To be eligible for this study you must:

• Be aged 18+ years old
• Intending to commence a prescription for a GLP-1 agonist (i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication for weight or diabetes management, with no use in the previous 6 months
• Willing to participate in dietary recall and questionnaires

To read the Participant Information Letter and find out if you are eligible, please complete the screening questionnaire here.

For more information, please contact Dr Evelyn Parr via email evelyn.parr@acu.edu.au or phone 03 9230 8278.

This study has been approved by the ACU Human Research Ethics Committee (2025-4090H).

Non-participant enquiry

If you are a healthcare professional or other interested person, to find out more please fill in the following information and a researcher will contact you shortly.